Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
JD HEALTH
06618
5
ALI HEALTH
00241
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 84.81%-27.08K | -3,214.92%-172.29K | 90.21%-109.48K | 76.12%-1.43M | 91.21%-136.29K | 90.79%-178.3K | 100.50%5.53K | 19.49%-1.12M | 13.38%-5.98M | 13.85%-1.55M |
| Net income from continuing operations | -651.71%-11.83M | -603.50%-693.81K | -115.52%-1.73M | 332.38%11.95M | 51.31%-1.46M | 210.05%2.14M | -93.65%137.8K | 570.97%11.13M | -944.85%-5.14M | -20.84%-3M |
| Operating gains losses | 166.99%233.19K | -13.97%183.96K | 101.06%165.87K | -790.76%-15.3M | 141.66%109.54K | 104.95%87.34K | --213.82K | ---15.71M | 82.42%-1.72M | --45.33K |
| Depreciation and amortization | -22.40%1.93K | -49.42%1.93K | -97.03%2.11K | -77.06%79.62K | -96.67%2.48K | -96.99%2.48K | -95.96%3.81K | -25.96%70.84K | -1.17%347.08K | -21.20%74.67K |
| Asset impairment expenditure | --12M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Unrealized gains and losses of investment securities | 78.13%-531.31K | 162.50%379.51K | -55.00%1.37M | --1.21M | -20.00%1.21M | -245.45%-2.43M | 85.19%-607.22K | 233.33%3.04M | --0 | 41.85%1.52M |
| Remuneration paid in stock | -83.80%2.75K | -88.47%4.2K | -48.66%6.73K | -75.02%76.53K | -61.96%9.98K | -60.52%16.97K | -51.36%36.46K | -91.91%13.12K | -28.96%306.39K | -42.85%26.22K |
| Other non cashItems | 91.82%-53 | 74.33%-201 | 62.36%-347 | -166.67%-2.86K | ---503 | ---648 | ---783 | ---922 | 96.99%-1.07K | ---- |
| Change In working capital | 25,238.38%99.55K | -121.60%-47.87K | -77.39%77.73K | 139.89%554.2K | 94.89%-10.87K | 97.87%-396 | -66.25%221.64K | 276.83%343.83K | 578.06%231.02K | 58.18%-212.67K |
| -Change in receivables | 330.59%18.24K | -101.33%-2.73K | 142.19%62.6K | -85.02%16.43K | -256.82%-32.67K | 68.87%-7.91K | 126.41%205.39K | -731.96%-148.38K | 132.89%109.62K | 104.38%20.83K |
| -Change in prepaid assets | 48.36%31.85K | -33.91%10.78K | -137.03%-36.93K | 649.36%144.38K | -28.65%6.88K | -29.79%21.47K | 141.26%16.31K | 436.80%99.72K | 111.37%19.27K | 109.85%9.65K |
| -Change in payables and accrued expense | 454.52%49.46K | -93,095.00%-55.92K | -86.74%52.06K | 285.15%393.39K | 106.14%14.92K | 41.19%-13.95K | -100.01%-60 | 265.96%392.49K | -77.52%102.14K | -476.91%-243.15K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 84.81%-27.08K | -3,214.92%-172.29K | 90.21%-109.48K | 76.12%-1.43M | 91.21%-136.29K | 90.79%-178.3K | 100.50%5.53K | 19.49%-1.12M | 13.38%-5.98M | 13.85%-1.55M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | -240K | 80.20%-200K | 42.85%-1M | 0 | 100.44%6.86K | 0 | -1,211.89%-1.01M | -125.20%-1.76M | 14.60%-105.89K |
| Net PPE purchase and sale | --0 | --0 | --0 | 101.96%4.87K | --0 | 114.98%6.86K | --0 | 97.42%-1.99K | 47.07%-249.06K | 14.60%-105.89K |
| Net business purchase and sale | --0 | ---240K | 80.16%-200K | 33.08%-1.01M | --0 | --0 | --0 | ---1.01M | -122.36%-1.51M | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | ---240K | 80.20%-200K | 42.85%-1M | --0 | 100.44%6.86K | --0 | -1,211.89%-1.01M | -125.20%-1.76M | 14.60%-105.89K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0.01%9.75K | -0.01%9.75K | -98.73%9.75K | -78.08%795.54K | -98.98%9.75K | -99.12%9.75K | -98.80%9.75K | 2.17%766.3K | -29.92%3.63M | 71.43%960K |
| Net issuance payments of debt | 0.01%9.75K | -0.01%9.75K | -49.99%9.75K | 221.83%48.73K | 124.37%9.75K | --9.75K | --9.75K | --19.49K | ---40K | ---40K |
| Proceeds from stock option exercised by employees | ---- | ---- | ---- | --0 | --0 | --0 | ---- | ---- | 0.00%60K | --0 |
| Net other financing activities | ---- | ---- | ---- | -79.31%746.81K | --0 | ---- | ---- | -0.43%746.81K | -29.49%3.61M | 100.00%1M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 0.01%9.75K | -0.01%9.75K | -98.73%9.75K | -78.08%795.54K | -98.98%9.75K | -99.12%9.75K | -98.80%9.75K | 2.17%766.3K | -29.92%3.63M | 71.43%960K |
| Net cash flow | ||||||||||
| Beginning cash position | -50.88%956.08K | -29.65%1.36M | -49.65%1.66M | -55.48%3.29M | -55.27%1.78M | -55.93%1.95M | -71.09%1.93M | -55.48%3.29M | 243.66%7.4M | -54.46%3.99M |
| Current changes in cash | 89.28%-17.33K | -2,734.95%-402.54K | 78.00%-299.74K | 60.15%-1.64M | 81.84%-126.54K | 93.20%-161.69K | 104.88%15.28K | -90.17%-1.36M | -178.24%-4.1M | 48.92%-696.79K |
| Cash adjustments other than cash changes | ---- | ---- | ---- | ---- | ---- | --0 | --0 | --337.5K | --3.01M | --3.01M |
| End cash Position | -47.41%938.75K | -50.88%956.08K | -29.65%1.36M | -49.65%1.66M | -49.65%1.66M | -55.27%1.78M | -55.93%1.95M | -71.09%1.93M | -55.48%3.29M | -55.48%3.29M |
| Free cash from | 84.81%-27.08K | -3,214.92%-172.29K | 90.23%-109.48K | 77.04%-1.43M | 91.77%-136.29K | 91.00%-178.3K | 100.49%5.53K | 23.58%-1.12M | 15.53%-6.23M | 13.90%-1.66M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.